At Diagenode we value excellence and disruptive science.
Diagenode has a solid track record in successful European project participation through the FP6, FP7 and H2020 programmes.
Contact firstname.lastname@example.org for enquiries related to collaborative research project applications.
Blueprint (for A BLUEPRINT of Hematopoietic Epigenomes) is a very ambitious and large-scale integrating project reuniting 41 partners, 52 PIs, representing 43 academic groups and 9 companies (mostly SMEs) from 12 countries over a 4-year period. Funded by the seventh Framework programme, the Blueprint consortium aims at generating 100 reference epigenomes of hematopoietic cells from healthy individuals and from leukaemic counterparts. This will ultimately leads to the discovery and validation of epigenetic markers for diagnostic use, as well as to the dissemination of a comprehensive set of epigenetic marks to the scientific community. In a collaborative effort requiring high quality standards, all partners are committed to use their state-of-the-art technologies to provide reference epigenomes and develop experimental and computational methods to improve epigenome detection , data analysis, storage and retrieval.
For more information, www.blueprint-epigenome.eu
IBD Character, A European Consortium to boost our understanding of Inflammatory Bowel Disease The Inflammatory Bowel Disease CHARACTERization by a multi-modal integrated biomarker study (IBD-Character) Consortium is a collaborative effort to advance our understanding of the inflammatory bowel diseases Ulcerative Colitis and Crohn's Disease and to increase diagnostic precision in detection of the diseases in their early manifestation. The consortium associates 10 European partners from both academia and industry. It was started with a € 6M grant thanks to the European Commission's 7th Framework Program (FP7). The project will generate the largest collection of samples so far assembled from treatment naïve patients recently diagnosed with inflammatory bowel disease. DNA methylation and RNA transcription status, protein markers, gut microbial content, patient genotype for known susceptibility loci and classical clinical data will be extensively analyzed for the characterization of the cohort in order to create a molecular snapshot of IBD in its early manifestation. This massive molecular profiling will be used to yield a list of biomarkers indicative for onset of the disease.
For more information, www.ibdcharacter.eu
Chromatin3D, Chromatin Dynamics in Development and Disease Most, if not all, DNA-dependent transactions must function within the context of chromatin. To do so, chromatin fibres must reversibly alternate between compact and relaxed structural states. The latter ensures that the underlying DNA sequences are properly exposed to protein complexes involved in transcription and replication, recombination or repair. Defects in DNA-templated processes are thought to be causal to a number of detrimental pathologies, including cancer. The Chromatin3D H2020 European Training Network focuses on a series of relatively short-term objectives that are achievable within the time course of the Network project. These objectives are centred to fifteen early stage researchers and are grouped into three broad thematic areas: The epigenetic regulation of developmental processes in the context of chromatin; The deregulated chromatin dynamics and the cause of disease; The development of novel approaches for the study of chromatin dynamics.
For more information, www.chromatin3d.eu
Epitrain, Training in Epigenetics of Common Disease The scope of EpiTrain European FP7 Innovative Training Network is to develop a broad scale understanding of epigenetic processes in common disease. The goal of the proposed network is to provide open training facilities for the next generation of researchers in the field of medical epigenetic research across a wide spectrum of research and develop synergies between the different research disciplines. The proposed network will also develop an open-access data management strategy to enable data storage and dissemination. The EpiTrain training program will increase the international competitiveness of European research in Epigenetics. We will integrate epidemiological, genetic and molecular techniques to study the molecular consequences of the gene-environment interactions on a large scale across a range of common diseases.
For more information, www.epitrain.eu
The mission of EpiTRAITS is to train young researchers in epigenetic gene regulation and flowering in the model plant Arabidopsis thaliana and the crop plants maize (Zea mays) and barley (Hordeum vulgare). Epigenetic gene regulation confers stability of gene expression patterns through cell divisions while allowing changes in expression in response to environmental or developmental cues. Although changes in epigenetic gene regulation are a major cause for trait variation, no rational strategies have been developed that utilize this knowledge for crop breeding purposes. The EpiTRAITS European FP7 Innovative Training Network will focus on one of the key plant traits, flowering, which is controlled by various epigenetic mechanisms. The scientific program aims to bridge the gap between fundamental and applied research by translating results from epigenetic research in model organisms to improved technologies for crop breeding and molecular diagnostic tools.
For more information, www.epitraits.eu
The NR-NET European FP7 Innovative Training Network is a multidisciplinary consortium, whose activities are directed towards the understanding of the role of Nuclear Receptors (NRs) and coregulators in metaflammatory disease. Metaflammation - metabolic disorders linked to chronic inflammation – is an emerging concept explaining the pathogenesis of a wide-spectrum of diseases. Since several nuclear receptors can directly sense metabolic alterations, they could be considered as important endogenous modulators of metaflammatory pathways further expanding the repertoire of diseases that can be intervened by NR-modulating drugs. The composition of the network is designed to contain a balanced mix of labs with experience and skills in academic and industry based research, so that it can provide young researchers the opportunity to acquire skills and expertise.
For more information, www.nr-net.gr
Cell-O-Matic, an exciting programme about single cell genomics
Diagenode is proud to be part of this consortium that will aim at developing chip-based technologies that process DNA from individual cells, ready for Next-Generation high-throughput sequencing.
Cell-O-Matic (High Throughput Systematic Single-cell Genomics using Micro/Nano-Fluidic Chips for Extracting, Pre-analysis, Selecting and Preparing Sequence-ready DNA) consortium is made up of 13 partners-2 academic research groups, 9 SME's and 2 industries- from 8 different member states and funded by the seventh Framework FP-HEALTH.2011. This consortium will aim at developing methods that enable whole chromosome lengths of DNA to be contiguously mapped using nanofluidics. The Cell-0-Matic project will also synergize efforts to develop chip-based technologies that process DNA from individual cells, ready for Next-Generation high-throughput sequencing. Hélène Pendeville Ph.D., R&D Manager Associate noted: "Improving the quality and throughput of sequencing technologies to access genome information at a single-cell level will have a profound impact on systems biology, including cancer. Diagenode is proud to be part of this exciting 4-year programme".
For more information, www.cellomatic.eu
NIPD-KIT, Development and validation of a non-invasive prenatal diagnostic (NIPD) kit for aneuploidy detection.
The companies Nipd Genetics Limited and Diagenode are joining forces through the H2020 EUREKA NIPD-KIT research collaborative project. The goal is to develop and validate a novel non-invasive prenatal diagnostic (NIPD) kit using taking advantage of the MeDIP principle for the enhanced detection of aneuploidies on chromosomes 21, 18, 13, X and Y for use in genetic diagnostic laboratories worldwide.
For more information, www.era-learn.eu/...nipd-kit-for-aneuploidy-detection
Using Methylated DNA Immunoprecipitation (MeDIP) in cancer for better clinical management. The MeDIP cancer consortium (CancerDip) project was supported by a grant from the European Commission as part of the seventh Framework programme (FP7). The project focused on optimizing and using the MeDIP technique to gather patient’s DNA methylation profile with the vision of using the data for personalized cancer treatment.
Heptromic: (for genomic predictors and oncogenic drivers in hepatocellular carcinoma) is a 3-year translational research which aims at defining biomarkers for identification of hepatocellular carcinomas patients with poor-prognosis and novel genetic and epigenetic drivers. These research findings will be incorporated in innovative predictive tools that will contribute better refinement of therapeutic strategies. Funded by the seventh Framework programme (FP7-HEALTH.2010) it brings together experts from five different European countries and one partner from the USA, including Diagenode.
For more information, www.heptromic.eu
The project (in the FP7 International Training Network (Mobility project) — DisChrom — Chromatin Diseases: from basic mechanisms to therapy) is focused on the definition of the epigenome in genetic pathologies resulting from mutations in structural components of chromatin (chromatin diseases). The scope of this ITN is to promote research and training in the field of chromatin diseases. Chromatin diseases (CD) are genetic pathologies resulting from mutations in structural components of chromatin or in enzymes that biochemically modify chromatin, altering chromatin status and thereby causing drastic effects on gene expression.
For more information, www.dischrom.eu
Led by the Second University of Naples, the ATLAS consortium includes partners in Spain, France, Romania, Lithuania, Belgium, Sweden, and the Netherlands, the ATLAS project aims at the development of Laser-Based Technologies and Prototype Instruments for Genome-Wide Chromatin Immunoprecipitation Analyses. The consortium will develop lasers that could induce DNA crosslinking for ChIP analyses of high precision and reproducibility, and extend the time range of such studies. The ATLAS consortium also will validate LaserChIP (LChIP) technologies and integrate them with irradiated frozen tissue slices and microfluidic cell sorting systems. Combining LChIP tools with proximity ligation will be used to analyze cell-selective epigenetic programs using small cell populations, down to the single-cell level. In ATLAS, Diagenode is focusing on 3 different aspects of the project:
Providing epigenetic research with high throughput technology on a genome-wide scale.
The ATLAS project was funded by the European seventh Framework programme.
For more information, www.atlas-eu.com
Providing epigenetic research with high throughput technology on a genome-wide scale. HEROIC is an Integrated Project supported by a grant from the European Commission as part of the sixth Framework programme (FP6). HEROIC encompasses 13 established research groups, from 8 European countries (The Netherlands, Austria, Sweden, Germany, United Kingdom, Belgium, Spain and France) all striving to further strengthen epigenetic research.
For more information, projects.ensembl.org/heroic/
The EPITRON project (Epigenetic treatment of neoplastic disease) was supported by a grant from the European Commission as part of the sixth Framework programme (FP6). The ultimate aim of the EPITRON project was to define and validate the concept of epigenetic treatment of cancer.